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Abstract; 
Background; chronic obstructive pulmonary disease (COPD) leads to significant morbidity and poor quality of 
life among patients. This study was conducted to evaluate serum magnesium levels among patients with COPD 
as there is no such study done in Pakistan on this topic. Material and Methods; A total of 137 patients 
presenting with COPD were registered from Department of medicine, Nishtar Hospital, Multan in this cross-
sectional study from June 2016 to June 2017. Once registered in the study, all the relevant baseline investigations 
were done. Venous blood sample was taken (3 ml) and sent to central laboratory of Nishtar Hospital Multan, for 
serum Mg levels. Statistical analysis was performed by entering all the data in SPSS version 20. Results; Of 
these 137 study cases, 84 (61.3%) were male patients while 53 (38.7%) were female patients. Mean age of our 
study cases was 56.79 ± 4.81 years. Of these 137 study cases, 41 (29.9%) were from rural areas while 96 
(70.1%) were from urban areas and 109 (79.6%) were poor. Diabetes was present in 28 (20.4%) and 
hypertension in 56 (40.9%) our patients. Mean height of our patients was 152.24 ± 10.87 centimeters while mean 
weight of our study cases was 66.41 ± 7.23 kilograms and mean body mass index was 24.87 ± 4.13 kg/m
2
. Our 
study results reported 66 (48.2 %) were normal weight, 41 (29.9 %) were overweight and 30 (21.9 %) were 
obese. Smoking was noted in 53 (38.7 %) of our study cases. Mean duration of illness was 30.81 ± 14.74 months 
and 112 (81.8%) had disease duration more than 18 months. Mean serum magnesium level of our patients was 
1.52 ± 0.54 meq/liter (Range; 1.15 meq/liter to 2.75 meq/liter) and hypomagnesemia was present in 50 (36.5 %) 
patients. Conclusion; Frequency of hypomagnsemia among patients with chronic obstructive pulmonary disease 
was very high in our study. Hypomagnesemia was significantly associated with male gender, increasing age, 
poor socioeconomic status, diabetes, hypertension, smoking and prolonged disease duration. Clinicians treating 
such patients should monitor their serum magnesium levels on regular basis to improve their prognosis and to 
decrease disease morbidity. 
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Introduction: 
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality 
worldwide, and represents a huge and growing economic and social burden 
1
. It is the fourth leading cause of 
death in the world and further increases its prevalence and mortality can be predicted in the coming decades 
2
. In 
2011, a major shift in Global Initiative for Chronic Obstructive Lung Disease (GOLD) treatment 
recommendations was proposed that stratifies patients with COPD on the basis of symptoms and exacerbation 
history 
3
. Chronic obstructive pulmonary disease has a rising incidence and is about to become the third leading 
cause of death worldwide in 2020. The disease is characterised by slowly progressive airflow obstruction, 
resulting in dyspnoea and exercise limitation 
4, 5
. Chronic obstructive pulmonary disease (COPD) represents an 
overlap of chronic bronchitis and emphysema, and patients with COPD have an element of asthmatic bronchitis. 
Bronchospasm is a contributing factor in their inability to clear secretions. This may result in reduced pulmonary 
gas exchange with consequences such as decreased quality of life and repeated hospitalization 
6
. A growing body 
of evidence suggests that Mg
+2
 deficiency contributes to exacerbations of asthma and, as a corollary, that Mg
+2
 is 
useful in alleviating bronchospasm in these patients. Magnesium is involved in such important functions as 
bronchodilation and contraction in respiratory tract smooth muscles, mast cell stabilization, neurohumoral 
mediator release, and mucociliary clearance. Magnesium is thought to have a protective effect against chronic 
respiratory tract diseases. It has been suggested that insufficient magnesium intake through diet may lead to 
development of asthma and COPD. However, insufficient information is available concerning the effect of 
magnesium on frequency of COPD 
7
. Thus, Mg
+2
 may have a role in maintaining disease stability in COPD 
patients. That not withstanding, the relationship between serum Mg
+2
 levels and outcome with regard to disease 
flares in COPD patients has not been, hitherto, thoroughly explored and a study demonstrated 35 % 
hypomagnesemia in COPD
 8
.  
Owing to the lack of local data this study was done to evaluate derangement in serum Mg levels among patients 
with COPD.  
 
Material and methods: 
A total of 137 patients presenting with COPD were registered from Department of Medicine, Nishtar Hospital, 
Multan. Known cases with asthma, pulmonary embolus, lung cancer and sleep apnea, patients with concomitant 
heart disease, confusion secondary to exacerbation of COPD and patients who were taking magnesium 
supplementation were excluded from our study. Once registered in the study, all the relevant baseline 
investigations were done. Venous blood sample was taken (3 ml) and sent to central laboratory of Nishtar 
Hospital Multan, for serum Mg levels. Statistical analysis was performed by entering all the data in SPSS version 
20.  
Results; 
Of these 137 study cases, 84 (61.3%) were male patients while 53 (38.7%) were female patients. Mean age of 
our study cases was 56.79 ± 4.81 years (with minimum age was 40 years while maximum age was 60 years). 
Mean age of the male patients was 58.69 ± 1.09 years while that of female patients was noted to be 53.77 ± 6.60 
years. Our study results have indicated that majority of our patients i.e. 122 (89.1%) belonged to the age group 
ranging 46 – 60 years. Of these 137 study cases, 41 (29.9%) were from rural areas while 96 (70.1%) were from 
urban areas and 109 (79.6%) were poor. Diabetes was present in 28 (20.4%) and hypertension in 56 (40.9%) our 
patients. Mean height of our patients was 152.24 ± 10.87 centimeters while mean weight of our study cases was 
66.41 ± 7.23 kilograms and mean body mass index was 24.87 ± 4.13 kg/m
2
. Our study results reported 66 (48.2 
%) were normal weight, 41 (29.9 %) were overweight and 30 (21.9 %) were obese. Smoking was noted in 53 
(38.7 %) of our study cases. Mean duration of illness was 30.81 ± 14.74 months and 112 (81.8%) had disease 
duration more than 18 months. Mean serum magnesium level of our patients was 1.52 ± 0.54 meq/liter (Range; 
1.15 meq/liter to 2.75 meq/liter) and hypomagnesemia was present in 50 (36.5 %) patients.  
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Table No. 1 Stratification of hypomagnesemia with regards to gender.  
Gender 
Hypomagnesemia   
P – value Yes  
(n = 50) 
No 
 (n = 87) 
Male 
(n = 84) 
46 38 
0.000 
Female 
(n = 53) 
04 49 
 
Total 
 
137  
Table No. 2 Stratification of hypomagnesemia with regards to age.  
Age groups 
Hypomagnesemia  
P – value Yes  
(n = 50) 
No 
 (n = 87) 
30 – 45 Years 
(n = 15) 
00 15 
0.001 
46 – 60 Years 
(n =  122) 
50 72 
 
Total 
 
137  
Table No. 3 Stratification of hypomagnesemia with regards to hypertension.  
Hypertension   
Hypomagnesemia   
P – value Yes  
(n = 50) 
No 
 (n = 87) 
Yes 
(n = 56) 
03 53 
0.000 
No 
(n = 81) 
47 34 
 
Total 
 
137  
Table No. 4 Stratification of hypomagnesemia with regards to obesity.  
Obesity 
Hypomagnesemia  
P – value Yes  
(n = 50) 
No 
 (n = 87) 
Normal weight 
(n = 66) 
08 58 
0.000 
Overweight 
(n = 41) 
12 29 
Obese 
(n = 30) 
30 00 
 
Total 
 
137  
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Table No. 5 
Stratification of hypomagnesemia with regards to disease duration.  
Disease duration 
Hypomagnesemia  
P – value Yes  
(n = 50) 
No 
 (n = 87) 
Up to 18 months 
(n = 25) 
00 25 
0.000 
More than 18 months 
(n = 112) 
50 62 
 
Total 
 
137  
Discussion; 
Currently the fifth leading cause of death and disease burden globally, COPD is characterized by significant 
physical and psychosocial challenges 
9, 10
. Our study comprised of a total of 137 study cases having COPD 
meeting inclusion criteria of our study. Of these 137 study cases, 84 (61.3%) were male patients while 53 
(38.7%) were female patients. Sertogullarindan et al 
2 
reported 56 % male gender predominance which is close to 
our study results. A study conducted by Gologanu et al 
11 
reported male gender predominance showing similar 
trends to our study. Maula et al 
 12 
also reported 65.4 % male patients with COPD showing male gender 
predominance which is in compliance with our study results. A study conducted by Waqas et al 
13
 has reported 
70 % male patients predominating over female gender with 30 % frequency, these findings are similar to that of 
our study results. Hassan et al 
14
 reported 53 % male patients with COPD which is same as that of our study 
results. Motiani et al 
15
 reported 80 % male patients compared with 20 % female patients with COPD which is 
showing same trend as that of our study results. Mean age of our study cases was 56.79 ± 4.81 years (with 
minimum age was 40 years while maximum age was 60 years). Mean age of the male patients was 58.69 ± 1.09 
years while that of female patients was noted to be 53.77 ± 6.60 years. Our study results have indicated that 
majority of our patients i.e. 122 (89.1%) belonged to the age group ranging 46 – 60 years. Gologanu et al 11 
reported 66.2 years which is higher than that being reported in our study. The reason for this difference is due to 
our inclusion criteria as we included only patients up to 60 years of age (30 – 60 years range). A study conducted 
by Maula et al 
12 
in Bannu reported 60.18 ± 11.67 years mean age which is close to our study results. 
Sertogullarindan et al 
2 
also reported 67 ± 10 years which is again slightly higher than our  findings. Phulpoto et 
al 
16
 reported 56.8 ± 7.8 years mean age of COPD patients, these findings are close to our study results. Motiani 
et al 
15
 reported 60.87±10.93 years mean age of the patients, which is similar to that of our study results. A study 
conducted by Mahishale et al 
17
 also reported 58 ± 9.6 years mean age which is close to our study results. 
Of these 137 study cases, 41 (29.9%) were from rural areas while 96 (70.1%) were from urban areas and 109 
(79.6%) were poor. Diabetes was present in 28 (20.4%) and hypertension in 56 (40.9%) our patients. Mean 
height of our patients was 152.24 ± 10.87 centimeters while mean weight of our study cases was 66.41 ± 7.23 
kilograms and mean body mass index was 24.87 ± 4.13 kg/m
2
. Our study results reported 66 (48.2 %) were 
normal weight, 41 (29.9 %) were overweight and 30 (21.9 %) were obese. Smoking was noted in 53 (38.7 %) of 
our study cases. Mean duration of illness was 30.81 ± 14.74 months and 112 (81.8%) had disease duration more 
than 18 months. A study conducted by Mahishale et al 
17
 also reported 21.24 % diabetes in patients with COPD 
which is close to our study results. Zaman et al 
18 
from Peshawar also reported 34 % smoking in these patients. A 
study conducted by Gumus et al 
7 
has also documented hypertension in 25 % while diabetes in 15 % patients 
with COPD which are consistent to our findings.  
Mean serum magnesium level of our patients was 1.52 ± 0.54 meq/L (Range; 1.15 meq/liter to 2.75 
meq/liter) and hypomagnesemia was present in 50 (36.5 %) patients. A study conducted by do Amaral et al
 8 
has 
reported 35 % hypomagnesemia in patients with COPD which is close to our study results. A study conducted by 
Gumus et al 
7 
reported
 
1.88 ± 0.26 meq/liter which is close to our findings. A study conducted by Singh et al 
 19 
from Jammu and Kashmir has reported 34 % hypomagnesemia which is close to our study results.  
Conclusion; Frequency of hypomagnsemia among patients with chronic obstructive pulmonary disease was very 
high in our study. Hypomagnesemia was significantly associated with male gender, increasing age, poor 
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socioeconomic status, diabetes, hypertension, smoking and prolonged disease duration. Clinicians treating such 
patients should monitor their serum magnesium levels on regular basis to improve their prognosis and to 
decrease disease morbidity. 
References; 
1. Zhang J, Lin XF, Bai CX. Comparison of clinical features between non-smokers with COPD and 
smokers with COPD: a retrospective observational study. Int J Chron Obstruct Pulmon Dis. 2014;9:57-
63. 
2. Sertogullarindan B, Gumrukcuoglu HA, Sezgi C, Akil MA. Frequency of pulmonary hypertension in 
patients with COPD due to biomass smoke and tobacco smoke. Int J Med Sci. 2012;9(6):406-12. 
3. Lee YM. Chronic obstructive pulmonary disease: respiratory review of 2014. Tuberc Respir Dis 
(Seoul). 2014;77(4):155-60.  
4. Vestbo J1, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the 
diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive 
summary. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65.  
5. Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest 
evidence and clinical implications. Ther Adv Chronic Dis. 2014;5(5):212–27.  
6. Thomsen M1, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers 
and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013 Jun 12;309(22):2353-61.  
7. Gumus A1, Haziroglu M1, Gunes Y2. Association of serum magnesium levels with frequency of acute 
exacerbations in chronic obstructive pulmonary disease: a prospective study. Pulm 
Med. 2014;2014:329476. doi: 10.1155/2014/329476.  
8. do Amaral AF, Gallo L, Vanucchi L, Crescincio JC, Vianna EO, Antonio J, et al. The effect of acute 
magnesium loading on the maximal exercise performance of stable chronic obstructive pulmonary 
disease patients. Clinics (Sao Paulo). 2012;67(6):615–21. 
9. Gegick S1, Coore HA, Bowling MR. Chronic obstructive pulmonary disease: epidemiology, 
management, and impact on North Carolina. N C Med J. 2013 Sep-Oct;74(5):411-4. 
10. Pleasants RA1, Herrick H, Liao W. The prevalence, characteristics, and impact of chronic obstructive 
pulmonary disease in North Carolina. N C Med J. 2013 Sep-Oct;74(5):376-83. 
11. Gologanu D, Stanescu C, Ursica T, Balea MI, Ionita D, Bogdan MA. Prevalence and characteristics of 
pulmonary hypertension associated with COPD - a pilot study in patients referred to a pulmonary 
rehabilitation program clinic. Maedica (Buchar). 2013;8(3):243-8. 
12. Maula F, Khan MN, Adil M, Ullah J, Rauf A, Samiullah. Echocardiographic findings in chronic 
obstructive pulmonary disease (COPD) patients. Pak J Chest Med. 2013;19(1): 
http://www.pjcm.net/index.php/pjcm/article/view/48/46. 
13. Waqas MS, Malik AN, Javed M. Effectiveness of conventional chest physiotherapy versus manual 
hyperinflation during postural drainage of ventilated COPD patients. Rawal Med J. 2014;39(1):32-4.  
14.  Hassan SH, Sheikh SA, Munfeat F. Spirometry and vital parameters in assessment of asthma and 
COPD in rural population of Karachi. Pak J Chest Med. 2007;13(1):15-20.  
15. Motiani B, Haidri FR, Rizvi N. Frequency of depression in chronic obstructive pulmonary disease 
(COPD) patients 
Pak J Med Sci. 2011;27(5):1112-5.  
16. Phulpoto MA1, Qayyum S, Rizvi N, Khuhawar SM. Proportion of gastroesophageal reflux symptoms in 
patients with chronic obstructive pulmonary disease. J Pak Med Assoc. 2005 Jul;55(7):276-9. 
17. Mahishale V1, Mahishale A2, Patil B1, Sindhuri A1, Eti A1. Screening for diabetes mellitus in patients 
with chronic obstructive pulmonary disease in tertiary care hospital in India. Niger Med J. 2015 Mar-
Apr;56(2):122-5.  
Journal of Medicine, Physiology and Biophysics                                                                                                                              www.iiste.org 
ISSN 2422-8427     An International Peer-reviewed Journal 
Vol.39, 2017 
 
107 
 
18. Zaman M, Wahab F, Khan N, Ashraf S. Management of patients admitted with COPD exacerbation in 
Chest Unit and Medical Units of Khyber Teaching Hospital, Peshawar. Pak J Chest Med. 
2007;13(4):11-6.  
19. Singh JP, Kohli S, Devi A, Mahajan S. Serum magnesium level in COPD patients attending a tertiary 
hospital – a cross – sectional study. Jammu Kashmir Sci. 2012;14(4):185-89. 
